Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

9 Months Ended

Sep. 30, 2016

Share Based Compensation Option And Incentive Plan [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity under the 2005 Plan, the 2014 Plan and the ESPP for the nine months ended September 30, 2016 and 2015:

					Weighted-Average
			Weighted-Average		Contractual Life
	Number of Options		Exercise Price		(In Years)
Nine Months Ended September 30, 2015
Outstanding at Beginning of Year		752,372	$	0.91		4.55
Granted		535,393		4.14		9.38
Exercised		(24,155)		0.65
Expired		(8,600)		0.65
Outstanding at End of Period		1,255,010	$	2.76		5.00

Exercisable at End of Period		870,810	$	2.89		5.27

Vested and Expected to Vest at End of Period		870,810	$	2.89		5.27

					Weighted-Average
			Weighted-Average		Contractual Life
	Number of Options		Exercise Price		(In Years)
Nine Months Ended September 30, 2016
Outstanding at Beginning of Year		1,277,367	$	2.75		4.94
Granted		355,071		2.81		9.50
Exercised		(86,765)		0.65
Forfeited		(12,362)		3.93
Outstanding at End of Period		1,533,311	$	2.91		6.44

Exercisable at End of Period		907,445	$	2.84		4.09

Vested and Expected to Vest at End of Period		1,533,311	$	2.91		6.44

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying Condensed Consolidated Statements of Operations and as follows:

	Nine Months Ended
	September 30,
	2016		2015
Research and Development	$	35,692	$	189,625
General and Administrative		354,777		955,231
	$	390,469	$	1,144,856